IN2014CN03925A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03925A
IN2014CN03925A IN3925CHN2014A IN2014CN03925A IN 2014CN03925 A IN2014CN03925 A IN 2014CN03925A IN 3925CHN2014 A IN3925CHN2014 A IN 3925CHN2014A IN 2014CN03925 A IN2014CN03925 A IN 2014CN03925A
Authority
IN
India
Prior art keywords
chimeric protein
dengue virus
create
virus
protein
Prior art date
Application number
Other languages
English (en)
Inventor
Sharon Isern
Scott F Michael
Original Assignee
Florida Gulf Coast University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florida Gulf Coast University filed Critical Florida Gulf Coast University
Publication of IN2014CN03925A publication Critical patent/IN2014CN03925A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN3925CHN2014 2011-10-25 2012-10-25 IN2014CN03925A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161550982P 2011-10-25 2011-10-25
PCT/US2012/061893 WO2013063248A1 (en) 2011-10-25 2012-10-25 Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes

Publications (1)

Publication Number Publication Date
IN2014CN03925A true IN2014CN03925A (es) 2015-07-03

Family

ID=48168485

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3925CHN2014 IN2014CN03925A (es) 2011-10-25 2012-10-25

Country Status (9)

Country Link
US (2) US20150265694A1 (es)
EP (1) EP2771366A4 (es)
CN (1) CN104736568A (es)
BR (1) BR112014009887A2 (es)
CR (1) CR20140189S (es)
HK (2) HK1198770A1 (es)
IN (1) IN2014CN03925A (es)
SG (1) SG11201401733VA (es)
WO (1) WO2013063248A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2014007864A0 (en) 2012-02-16 2014-08-31 Vlp Therapeutics Llc Virus like particle composition
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CN106795513B (zh) 2014-08-08 2021-06-11 Vlp治疗公司 包含修饰的包膜蛋白e3的病毒样颗粒
MX2017003117A (es) 2014-09-11 2017-06-14 Vlp Therapeutics Llc Particula tipo virus de flavivirus.
CN105732777B (zh) * 2016-05-05 2019-06-04 中国人民解放军军事医学科学院微生物流行病研究所 黄热病毒特异性检测抗原及其应用
EP3621645A4 (en) * 2017-05-10 2021-01-27 University of Massachusetts BIVALENT DENGUE / HEPATITIS B VACCINES
CN113429479B (zh) * 2018-04-04 2023-03-10 中国科学院微生物研究所 一种高灵敏度的黄热病毒人源单克隆抗体及其应用
CN109627294B (zh) * 2018-12-29 2020-10-09 四川大学 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
ES2439724T3 (es) * 2001-06-01 2014-01-24 Sanofi Pasteur Biologics, Llc Vectores de flavivirus quiméricos
CN101287490B (zh) * 2005-08-10 2013-04-24 阿坎姆比斯公司 对抗登革热病毒感染的疫苗接种

Also Published As

Publication number Publication date
US20150265694A1 (en) 2015-09-24
US10124053B2 (en) 2018-11-13
HK1206366A1 (en) 2016-01-08
US20170202945A1 (en) 2017-07-20
CN104736568A (zh) 2015-06-24
BR112014009887A2 (pt) 2017-04-25
SG11201401733VA (en) 2014-09-26
WO2013063248A1 (en) 2013-05-02
CR20140189S (es) 2014-09-24
EP2771366A1 (en) 2014-09-03
EP2771366A4 (en) 2015-06-03
HK1198770A1 (en) 2015-07-31

Similar Documents

Publication Publication Date Title
IN2014CN03925A (es)
TN2015000185A1 (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
UA116087C2 (uk) Композиція для лікування вірусу гепатиту c
MX346264B (es) Compuestos antivirales.
TN2013000485A1 (en) 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
EA029939B8 (ru) Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение
MX358099B (es) Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.
EA201270616A1 (ru) Ингибиторы вируса гепатита с
IN2014CN03113A (es)
PH12015502230A1 (en) Novel viral replication inhibitors
PH12014502628A1 (en) Compositions and methods related to the prevention and treatment of rabies infection
MX2013012233A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
PH12015501076A1 (en) N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group
CL2012000783A1 (es) Proceso para mejorar la eficacia de proteccion metodo para inducir una respuesta inmune contra el virus del dengue que comprende vacunas de dna y virus quimericos 17d; composicion vacunal que comprende vacunas de dna contra los cuatro serotipos del virus dengue y virus quimericos comprendiendo el virus vacunal de fiebre amarilla; plasmido recombinante conteniendo el gen de la proteína e.
MX2014009022A (es) Virus de influenza c y vacuna.
WO2014201027A3 (en) Treatment of merkel cell polyomavirus infection
BR112013007308A2 (pt) vacina
MY164064A (en) Anti-viral compounds
MY171384A (en) Composition and methods related to the prevention and treatment of rabies infection
TN2013000453A1 (en) Hepatitis c virus inhibitors
MX358496B (es) Terapeuticos a base de levadura para infeccion de la hepatitis b cronica.
UA67522U (ru) Способ повышения чувствительности к цефатоксиму музейного штамма золотистого стафилококка атсс 25923